Sponsored by:THE MEDICAL EDUCATOR CONSORTIUM

10TH ANNUAL CALIfORNIA CANCER CONSORTIUM CONfERENCE

“Recent Advances and New Directions in Cancer Therapy”

August 8-10, 2014The Westin Pasadena

Pasadena, CA

Presented by the California Cancer Consortium

University of California Davis Comprehensive Cancer Center, Sacramento, CA

City of Hope Comprehensive Cancer CenterDuarte, CA

University of Southern California/Norris Comprehensive Cancer Center

Los Angeles, CA

University of Pittsburgh Cancer Institute/UPMCPittsburgh, PA

Barbara Ann Karmanos Comprehensive Cancer Center (Wayne State University), Detroit, MI

Penn State Hershey Cancer Institute (Penn State University), Hershey, PA

Program Chairs:Primo Lara, Jr., M.D. | Edward Newman, Ph.D.

Steering Committee:Chandra Belani, M.D. | Edward Chu, M.D.

David Gandara, M.D. | Heinz-Josef Lenz, MD, Ph.D.Patricia LoRusso, D.O. | Robert Morgan, M.D.

PROGRAM CHAIRSPrimo Lara, Jr., M.D.Professor of MedicineUniversity of California Davis School of MedicineAssociate Director for Translational ResearchUniversity of California Davis Comprehensive Cancer Center

Edward Newman, Ph.D.Associate Professor, Molecular Pharmacology Co-director, Analytical Pharmacology Core Facility City of Hope Comprehensive Cancer Center

STEERING COMMITTEEChandra Belani, M.D.Miriam Beckner Distinguished Professor of MedicinePenn State Milton S. Hershey Medical Center Deputy DirectorPenn State Hershey Cancer Institute

Edward Chu, M.D.Professor and Chief of Hematology/OncologyUniversity of Pittsburgh School of MedicineDeputy Director, University of Pittsburgh Cancer Institute

David Gandara, M.D.Professor of MedicineUniversity of California Davis School of MedicineSenior Advisor to the DirectorUniversity of California Davis Comprehensive Cancer Center

Heinz-Josef Lenz, M.D., Ph.D.Professor of Medicine and Preventive Medicine, Section Head of GI OncologyUniversity of Southern California, Keck School of MedicineAssociate Director for Clinical Research, University of Southern California Norris Comprehensive Cancer Center

Patricia LoRusso, D.O.Professor of MedicineWayne State University School of Medicine Director, Center for Experimental Therapeutics, Karmanos Cancer Institute

Robert Morgan, M.D.Professor of MedicineCo-director, Gynecological Cancers Program City of Hope Comprehensive Cancer Center

DISTINGUISHED fACULTyLeonard Appleman, M.D.Assistant ProfessorUniversity of Pittsburgh School of MedicineUniversity of Pittsburgh Cancer Institute

Chandra Belani, M.D.Miriam Beckner Distinguished Professor of MedicinePenn State Milton S. Hershey Medical Center Deputy DirectorPenn State Hershey Cancer Institute

Suzette Blanchard, Ph.D.Assistant Professor and Senior BiostatisticianCity of Hope Comprehensive Cancer Center

Alice Chen, M.D.Senior InvestigatorCTEP, National Cancer Institute

Helen Chew, M.D.Professor of MedicineUniversity of California Davis School of Medicine

Diana Chingos, MS, MfAPatient AdvocateUniversity of Southern California and Young Survival Coalition

Tanya Dorff, M.D.Assistant ProfessorUniversity of Southern California Keck School of MedicineNorris Comprehensive Cancer Center

Anthony El-Khoueiry, M.D.Assistant ProfessorUniversity of Southern California Keck School of MedicineNorris Comprehensive Cancer Center

Stephen forman, M.D. Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell TransplantationCo-leader, Hematologic Malignancies ProgramCity of Hope Comprehensive Cancer Center

Paul frankel, Ph.D.Senior Biostatistician, Division of Biostatistics, Department of Information SciencesBeckman Research Institute, City of Hope Comprehensive Cancer Center

Shirish Gadgeel, M.D.Leader, Thoracic Oncology Multidisci-plinary Team, Barbara Ann Karmanos Cancer CenterAssociate Professor, Wayne State University School of Medicine

David Gandara, M.D.Professor of Medicine, University of California Davis School of MedicineSenior Advisor to the Director, University of California Davis Comprehensive Cancer Center

Susan Groshen, Ph.D.Professor of Medicine and Director, Biostatistics CoreUniversity Southern California Norris Comprehensive Cancer Center

Elisabeth Heath, M.D.Associate Professor of Oncology, Wayne State University School of MedicineBarbara Ann Karmanos Cancer Center

Brian Jonas, M.D., Ph.D.Assistant Professor, University of California Davis School of MedicineUniversity of California Davis Comprehensive Cancer Center

Monica Joshi, M.D.Assistant ProfessorPenn State University Hershey School of Medicine, Penn State Hershey Cancer Institute

Karen Kelly, M.D. Professor of Medicine, University of California Davis School of MedicineAssociate Director of Clinical Research, University of California Davis Comprehensive Cancer Center

friedrich Knollman, M.D., Ph.D. Professor of Clinical Radiology, University of California Davis School of Medicine

Marianna Koczywas, M.D.Clinical Professor of MedicineCity of Hope Comprehensive Cancer Center

Primo Lara, Jr., M.D.Professor of Medicine, University of California Davis School of MedicineAssociate Director for Translational Research, University of California Davis Comprehensive Cancer Center

Heinz-Josef Lenz, M.D., Ph.D.Professor of Medicine and Preventive Medicine, Section Head of GI Oncology, University of Southern California, Keck School of MedicineAssociate Director for Clinical ResearchUniversity Southern California Norris Comprehensive Cancer Center

Tianhong Li, M.D., Ph.D.Assistant Professor, University of California Davis School of MedicineUniversity of California Davis Comprehensive Cancer Center

Xin Liu, M.D.Assistant ProfessorPenn State University Hershey School of Medicine, Penn State Hershey Cancer Institute

Jeffrey Longmate, Ph.D.Professor and Director, Division of Biostatistics, Department of Information SciencesBeckman Research Institute, City of Hope Comprehensive Cancer Center

Patricia LoRusso, D.O.Professor of Medicine, Wayne State University School of MedicineDirector, Center for Experimental TherapeuticsBarbara Ann Karmanos Cancer Institute

Philip Mack, Ph.D.Associate Professor of Medicine, University of California Davis School of Medicine DirectorCancer Molecular PharmacologyUniversity of California Davis Comprehensive Cancer Center

Kim Margolin, M.D.Professor of MedicineUniversity of Washington School of MedicineFred Hutchinson Cancer Research CenterSeattle Cancer Care Alliance

Robert Morgan, M.D.Professor of Medicine, Department of Medical Oncology and Therapeutics Research Co-director, Gynecological Cancers Program City of Hope Comprehensive Cancer Center

Edward Newman, Ph.D.Associate Professor, Molecular Pharmacology Co-director, Analytical Pharmacology Core Facility City of Hope Comprehensive Cancer Center

Amit Oza, M.D.Senior Staff Physician and Professor of MedicinePrincess Margaret Hospital, University of Toronto School of Medicine

Sumanta Pal, M.D.Assistant Professor, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer Center

Philip Philip, M.D.Professor of Medicine, Wayne State University School of Medicine Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute

Jacek Pinski, M.D, Ph.D.Associate Professor of Medicine Co-director, Prostate Cancer Research Program USC Norris Comprehensive Cancer Center

David Quinn, MBBS, Ph.D.Associate Professor and Head, Section of GU Medical Oncology, USC Keck School of Medicine Leader, Developmental Therapeutics Program University of Southern Cali-fornia Norris Comprehensive Cancer Center

Karen Reckamp, M.D.Co-director, Lung Cancer and Thoracic Oncology Program Associate Professor, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer Center

Jonathan Riess, M.D.Assistant Professor, University of California Davis School of MedicineUniversity of California Davis Comprehensive Cancer Center

Lynda Roman, M.D.Associate Professor and DirectorDivision of Obstetrics and GynecologyUSC Keck School of MedicineUSC Norris Comprehensive Cancer Center

Thomas Semrad, M.D.Assistant Professor, UC Davis School of MedicineUniversity of California Davis Comprehensive Cancer Center,

Tanya Siddiqi, M.D.Assistant Professor, Department of Hematology & Hematopoietic Cell TransplantationCity of Hope Comprehensive Cancer Center

George Somlo, M.D.Professor, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer Center

Timothy Synold, PharmDCo-director, Analytical Pharmacology Core Facility Associate Professor, Molecular PharmacologyCity of Hope Comprehensive Cancer Center

Ahmad Tarhini, M.D.Associate Professor of Medicine,Clinical and Translational ScienceUniversity of Pittsburgh School of Medicine

Joseph Tuscano, M.D.Professor of Medicine, University of California Davis School of MedicineUniversity of California Davis Comprehensive Cancer Center

Przemyslaw Twardowski, M.D.Associate Professor, Department of Medical Oncology and Therapeutics ResearchCity of Hope Comprehensive Cancer Center

Ulka Vaishampayan, M.D.Associate Professor of MedicineWayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute

10th Annual California Cancer Consortium Conference

“Recent Advances and New Directions in Cancer Therapy”

COURSE DESCRIPTIONThis conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

EDUCATIONAL OBJECTIVESAfter participating in this educational activity, you should be able to:

• Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of many individual tumor types, and identify specific opportunities for therapeutic intervention.

• Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of your patients with cancer.

• Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of your patients with cancer.

• Discuss the new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

TARGET AUDIENCEThis program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

NEEDS ASSESSMENTThis course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology,

biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently improve patient outcomes.

ACCREDITATIONThe Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT HOURSThe Medical Educator Consortium designates this educational activity for a maximum of 15 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSUREThe Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.

10th Annual California Cancer Consortium Conference “Recent Advances and New Directions in Cancer Therapy”

9:30 am - 12:30 pm Industry Advisory Board Block (by invitation only)2:00 pm Registration & Visit Exhibits3:30 pm Welcome and Introductions3:35 pm Pre-session Survey

Session 1: Inhibition of Signal Transduction and Angiogenesis PathwaysChairs: Primo Lara Jr., M.D., (UC Davis) and Edward Newman, Ph.D., (City of Hope)

3:40 pm EGFR and Met Inhibitors: State of the Art Karen Reckamp, M.D., City of Hope 3:50 pm Question-and-Answer Session3:55 pm PI3K/Akt and Related Pathways: Novel Therapeutics Leonard Appleman, University of Pittsburgh4:05 pm Question-and-Answer Session4:10 pm FGF and FGFR as Therapeutic Targets Thomas Semrad, M.D., UC Davis4:20 pm Question-and-Answer Session4:25 pm New Vascular/Angiogenesis -Targeted Therapies Tanya Dorff, M.D., USC4:35 pm Question-and-Answer Session4:40 pm mTOR inhibitors: Latest and Greatest Sumanta Pal, M.D., City of Hope4:50 pm Question-and-Answer Session5:00 pm Refreshment Break & Visit Exhibits

Session 2: Clinical Trial DesignChairs: Jeffrey Longmate, Ph.D., (City of Hope) and Paul frankel, Ph.D., (City of Hope)

5:15 pm Integration of New Clinical Trial Designs for Early Drug Development Suzette Blanchard, Ph.D., City of Hope 5:25 pm Question-and-Answer Session5:35 pm Statistical Designs for Biomarker Development Susan Groshen, Ph.D., USC5:45 pm Question-and-Answer Session5:55 pm Rebiopsies and Serial Biopsies in Clinical Trials Diana Chingos, MS, MFA, USC6:05 pm Question-and-Answer Session6:10 pm Cancer Imaging in the Molecular-Targeted Era Friedrich Knollman, M.D., Ph.D. (UC Davis)6:20 pm Question-and-Answer Session6:25 pm Roundtable Discussion: Novel Paradigms in Early Drug Development Moderator: Jeffrey Longmate, Ph.D., City of Hope

Participants: Edward Newman, Ph.D. Paul Frankel, Ph.D., Suzette Blanchard, Ph.D. Susan Groshen, Ph.D., David Gandara, M.D. Themes: (1) Phase 0 Trials (2) Molecular Enrichment Strategies (3) Cytostatic Therapy Assessment 6:45 pm Question-and-Answer Session6:50 pm Post-session Survey7:00 pm - 9:00 pm Wine and Cheese Welcome Reception & Visit Exhibits

fRIDAy, AUGUST 8TH, 2014

CONfERENCE AGENDA

6:30 am Registration, Refreshments & Visit Exhibits7:15 am – 8:00am Breakfast Symposia (non CME)8:00 am Introduction8:05 am Pre-session Survey

Session 3: Cancer Immunotherapy Chairs: Chandra Belani, M.D., (Penn State) and Tianhong Li, M.D., Ph.D., (UC Davis)

8:10 am Genetically Modified T Cells for Treatment of Cancer Stephen Forman, M.D., City of Hope8:25 am Question-and-Answer Session 8:30 am PD-1 and PDL-1 Targeted Therapy Karen Kelly, M.D., UC Davis8:40 am Question-and-Answer Session 8:45 am Vaccine and Dendritic Cell Approaches Przemyslaw Twardowski, M.D., City of Hope 8:55 am Question and Answer9:00 am CTLA4 and other Novel Immunotherapeutic Approaches (IDO, etc) Elisabeth Heath, M.D., Wayne State9:10 am Question and Answer

Session 4: Lung Cancer Chairs: Mariana Koczywas, M.D., (City of Hope) and Jonathan Riess, M.D., (UC Davis)

9:20 am Linking Molecular Biology to Cancer Therapeutics in NSCLC David Gandara, M.D.,UC Davis9:40 am Question-and-Answer Session9:45 am Squamous Cell Lung Cancer: Current and Future Directions Chandra Belani, M.D., Penn State10:05 am Question-and-Answer Session10:10 am Small Cell Lung Cancer: Emerging Therapeutics Shirish Gadgeel, M.D., Wayne State10:20 am Question and Answer 10:25 am Refreshment Break & Visit Exhibits

Session 5: Gastrointestinal Malignancies Chairs: Thomas Semrad, M.D., (UC Davis) and Anthony El-Khoueiri, M.D., (USC)

10:45 am Keynote Lecture: Novel Approaches to the Treatment of Colorectal Carcinoma Heinz-Josef Lenz, M.D., Ph.D., USC11:05 am Question-and-Answer Session11:10 am New Developments in Pancreatic Cancer Philip Philip, M.D., Wayne State11:25 am Question-and-Answer Session

Session 6: Hematologic MalignanciesChair: Brian Jonas, M.D., Ph.D., (UC Davis)

11:30 am Drug Development in Lymphoid Malignancies: Implications for Personalized Therapy Tanya Siddiqi, M.D., City of Hope 11:50 am Question-and-Answer Session11:55 am Non-Hodgkin Lymphoma: Current and Future Directions Joseph Tuscano, M.D., UC Davis

SATURDAy, AUGUST 9TH, 2014

CONfERENCE AGENDA

12:10 pm Question-and-Answer Session12:15pm Refreshments & Visit Exhibits12:30 pm Lunch Symposia (non cme)

Session 7: Genitourinary MalignanciesChairs: Przemyslaw Twardowski, M.D., (City of Hope), Monica Joshi, M.D., (Penn State)

1:15 pm Updates on Castration Resistant Prostate Cancer Therapy David Quinn, MBBS, Ph.D., USC1:35 pm Question-and-Answer Session1:40 pm Updates in Renal Cell Carcinoma Drug Development Sumanta Pal, M.D., City of Hope 1:55 pm Question-and-Answer Session

Session 8: Melanoma Chair: Edward Newman, Ph.D., (City of Hope)

2:00 pm BRAF Inhibition in Melanoma Ahmad Tarhini, M.D., University of Pittsburgh2:15 pm Question-and-Answer Session2:20 pm Beyond BRAF: New Innovations in Melanoma Kim Margolin, M.D., University of Washington2:35 pm Question-and-Answer Session

Session 9: Gynecologic CancerChair: Lynda Roman, M.D. (USC)

2:40 pm Management of Ovarian Cancer in 2014 Robert Morgan, M.D., City of Hope2:55 pm Question-and-Answer Session3:00 pm New Approaches to Cervix and Endometrial Cancer Amit Oza, M.D., Princess Margaret Hospital3:15 pm Question-and-Answer Session3:20 pm Adjourn 3:30 – 6:30 pm Industry Advisory Board Block (by invitation only) 7:30-10 pm CCCP Dinner (Newman Residence)

6:30 am Registration, Refreshments & Visit Exhibits7:15am – 8:00am Breakfast Symposia (non cme)8:00 am Introduction8:05 am Pre-session Survey

Session 9: Endocrine-Driven Cancers (with emphasis on Breast Cancer)Chairs: George Somlo,M.D., (City of Hope), Primo Lara, Jr., M.D., (UC Davis)

8:10 am Keynote Lecture: New Approaches to Breast Cancer Based on Molecular Profiling Helen Chew, M.D., UC Davis8:25 am Question-and-Answer Session8:30 am Prostate Cancer: Translating New Biologic Findings Into New Therapies Jacek Pinski, M.D., Ph.D., USC8:50 am Question-and-Answer Session

SUNDAy, AUGUST 10TH, 2014

CONfERENCE AGENDA

Session 10: Emerging Therapeutic Strategies in Oncology

8:55 am Keynote Lecture: New Concepts in Overcoming Drug Resistance TBA9:15 am Question-and-Answer Session9:20 am Antibody-Drug Conjugates in Solid Tumors Ulka Vaishampayan, M.D., Wayne State9:35 am Question-and-Answer Session9:40 am Antibody-Drug Conjugates and Peptibodies in Hematologic Malignancies Joseph Tuscano, M.D., UC Davis9:55 am Question-and-Answer Session10:00 am Targeting DNA Repair in Cancer Therapeutics Phillip Mack, Ph.D., UC Davis 10:15 am Question-and-Answer Session10:20 am Refreshment Break & Visit Exhibits

Session 11: Integration of ‘Omics and Biomarkers into Clinical Trials and Patient CareChairs: Timothy Synold, PharmD, (City of Hope), Edward Newman, Ph.D., (City of Hope)

10:30 am Keynote Lecture: Personalizing Cancer Therapy: The NCI Empact and Match trials Alice Chen, M.D., National Cancer Institute10:45 am Molecular Phenotyping Platforms: What to Use and When Philip Mack, Ph.D., UC Davis10:55 am Pharmacogenomics: Clinical Applications Timothy Synold, PharmD, City of Hope11:05 am Circulating Tumor Cells: Relevance to Clinical Practice and Research Xin Liu, M.D., Penn State11:15 am Roundtable Discussion and Question and Answer Session Theme: Best Practice Models for Biomarker and ‘Omics Technology Deployment in the Clinic and in Clinical Trials

Session 12: New Agents in DevelopmentChairs: Heinz-Josef LenzM.D., Ph.D., (USC), Pat LoRusso (Wayne State)

11:30 am MEK inhibitors Monica Joshi, M.D., Penn State11:40 am HSP90 inhibitors Anthony El-Khoueiry, M.D., USC 11:50 am Novel or reformulated cytotoxics (e.g., nab-paclitaxel, folate targeted agents) Shirish Gadgeel, M.D., Wayne State12:00 pm ALK inhibitors Tianhong Li, M.D., Ph.D., UC Davis12:10 pm Targeting epigenetics (Bromodomain inhibitors, HDAC inhibitors, etc) Jonathan Riess, M.D., UC Davis12:20 pm Question-and-Answer Session12:30 pm Adjourn

SUNDAy, AUGUST 10TH, 2014 Continued

CONfERENCE AGENDA

The Westin Pasadena welcomes guests with a full complement of facilities and amenities, all designed to ensure you leave feeling better than when you arrived. We prioritize convenience and simplicity with our 24-hour Business Center, where you can put tasks behind you with

ease, as well as Concierge services, for professional guidance on enjoying the best Pasadena has to offer. For reenergizing and clearing your mind, take advantage of our light-filled WestinWORKOUT® Fitness Studio and our alluring outdoor heated pool, with gorgeous views.

Enjoy some of the finest views of the San Gabriel Mountains and the Pasadena area from The Westin Pasadena, or step out to partake in the colorful spirit of downtown. Shoppers and food-lovers alike will revel in the remarkable range of options surrounding us. Just a few minutes on foot from the hotel, the Paseo Colorado features premier dining and retail outlets plus a cinema. Less than a mile away, historic Old Pasadena’s charming storefronts house 200 shops plus a wide array of restaurants and night spots.

The Westin is located within walking distance of the Pacific Asia Museum areas, while the California Technical Institute, the historic Tournament of Roses house, and the Norton Simon Museum are all less than two miles away. A ten-minute drive will take you to the resplendent Huntington Library, with its extensive art collections and botanical gardens.

Golf enthusiasts will enjoy the 36-hole, William P. Bell-designed Brookside Golf Club, just a five-minute drive away. The nine-hole Eaton Canyon course is 15 minutes away in the San Gabriel foothills, and Santa Anita Park—a famous thoroughbred racetrack—is equally close by. The Rose Bowl, a world-famous sports and entertainment venue boasting beautiful greenery and cliff sides, is only five minutes away by car.

The Westin Pasadena is offering special rates during this conference of $159 single or double room plus tax, European Plan (no meals). The cutoff date to make reservations is July 18th, 2014, after this date reservations are subject to hotel availability.

Make your hotel reservations by calling 866.837.4181 and use group code “CA Cancer Consortium Conference”

CONfERENCE MANAGEMENTMEETING EVENTS & CONFERENCE COORDINATORS, INC (MECC)

1550 S Dixie Highway Suite 202Coral Gables, FL 33146

Telephone: 305.663.1628Fax: 305.675.2718

Website: www.meccinc.comEmail: tvalls@meccinc.com

Register online at www.meccinc.com under upcoming events.

THE WESTIN PASADENA191 N Los Robles AvenuePasadena, CA 91101

Reservation: 866.837.4181

HOTEL INfORMATION

Name _______________________________________________ Degree ______________

License Number _________________________________ State______________________

Address __________________________________________________________________

Telephone (____) ____________________________ Fax (____) _____________________

Email ___________________________________________________________________

Specialty _________________________________________________________________

TyPE Of PRACTICE: o Private o Academic o Hospital o Other

REGISTRATION fEE: o $175 Physician o $ 75 Nurse, Nurse Practitioner, Resident, Fellow, Students, Non-physician researchers and staff (e.g., CRAs) o $250 Industry Professional o $ 25 Per person (Saturday night dinner)

Refunds must be provided in writing prior to July 8th, 2014. A $50 administrative charge will be deducted for all refunds prior to July 8th, after July 8th no refunds will be provided.

Enclosed is my check i/a/of $___________ for the registration of this conference.

I authorize MECC to charge my credit card i/a/o $__________ for the registration of this course using the following credit card.

Name as it appear on the card _____________________________ Exp. Date ___________

Card number _____________________________________________________________

Authorized signature ________________________________________________________

for those requiring special assistance, contact MECCat 305.663.1628 or via email tvalls@meccinc.com no later than July 8th, 2014.

Registration Form

10th Annual California Cancer Consortium Conference “Recent Advances and New Directions in Cancer Therapy”

August 8-10, 2014, The Westin Pasadena, Pasadena, CA

Mee

ting

s, E

vent

s an

d C

onfe

renc

e C

oord

inat

ors,

Inc

.P.

O. B

ox 4

3037

6M

iam

i, FL

332

43-0

376

____

____

____

_PR

ST S

TD

US

Post

age

PAID

Mia

mi,

FLPe

rmit

No.

142

9

“Rec

ent A

dvan

ces a

nd N

ew D

irecti

ons i

n C

ance

r The

rapy

”10

TH AN

NUAL

CAL

IfO

RNIA

CAN

CER

CONS

ORT

IUM

CO

NfER

ENCE

Augu

st 8-

10, 2

014

The W

estin

Pas

aden

a, Pa

sade

na, C

A